AAM
IOBT

Aureus Asset Management’s IO Biotech IOBT Stock Holding History

Aureus Asset Management’s Portfolio IOBT Stock Details IOBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-43,744
Closed -$85.5K – 198
2023
Q2 		$85.5K Buy
+43,744
New +$85.5K 0.01% 182

Other funds holding IOBT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Aureus Asset Management's IOBT Position: Q3 2023 in Review

Aureus Asset Management sold out of IO Biotech (IOBT) in Q3 2023, closing a stake of 43,744 shares — an estimated $85.5K sold.

Aureus Asset Management first reported a position in IOBT in Q2 2023 and held it in 1 quarter. The position peaked at $85.5K in Q2 2023. 19 funds tracked by Wall St. Rank hold IOBT as of Q3 2023.

  • Aureus Asset Management reported no remaining IO Biotech position as of Q3 2023 after selling out during the quarter.
  • Aureus Asset Management sold 43,744 IO Biotech shares in Q3 2023, an estimated $85.5K.
  • Aureus Asset Management first reported a position in IO Biotech in Q2 2023 and held it in 1 quarter.
  • Aureus Asset Management's IO Biotech position peaked at $85.5K in Q2 2023.
  • 19 funds tracked by Wall St. Rank held IO Biotech as of Q3 2023.

Based on Aureus Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.